ClinicalTrials.gg
CompletedNCT01668797EQUATORUpdated Jan 13, 2017Results posted

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

A Phase 3 interventional study of Brexpiprazole and Placebo in Acute Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 49 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
524
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
4th of 28
524 · median 155
Started
2012
the only one that year
Phase 3
16 of 28
none open now
Registered
12th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2012, is one of 16 in phase 3, and was the 12th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.

Read the detailed description

Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.

03

Conditions studied

  • Acute Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age 18 years or older to less than 65 years, inclusive (at time of )
  • Subjects with a current diagnosis of schizophrenia, as defined by criteria and a history of the illness for at least three years prior to screening (as per subject, family, healthcare provider, or by previous medical records).
  • Subjects with a stable living environment, as demonstrated by the ability to provide contact information for themselves and/or family/friend(s)/caregiver(s).
  • Subjects who showed previous response to antipsychotic treatment in the past year.
  • Subjects who are currently treated with oral or depot antipsychotics other than clozapine or who have had a recent lapse in antipsychotic treatment requiring chronic treatment with antipsychotic medication for stabilization.
  • Subjects who are experiencing a current acute exacerbation of psychotic symptoms requiring stabilization
  • Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.

Exclusion criteria

Exclusion Criteria:

  • Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving medicinal product
  • Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator
  • Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)
  • Subjects experiencing acute depressive symptoms within the past 30 days
  • Subjects with schizophrenia who are considered resistant/ to antipsychotic treatment by history
  • Subjects with a significant risk of violent behavior; who represent a risk of committing suicide
  • Subjects with tardive dyskinesia
  • Subjects currently treated with insulin for diabetes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
524 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo comparator for 52 weeks

    Drug: Placebo

  • Experimental
    Brexpiprazole (OPC-34712)

    Brexpiprazole (OPC-34712) for 52 weeks

    Drug: Brexpiprazole

Interventions

  • Brexpiprazole tablets 1 to 4 mg /day

  • DrugPlacebo

    Placebo comparator for 52 weeks

06

What researchers measure

Primary outcomes

  1. Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C.

    The primary efficacy variable was time to impending relapse from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \>4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content).OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.The measure type, number is Hazard Ratio.

    Time frame: From randomization to time of exacerbation of psychotic symptoms/impending relapse - up to 52 weeks

Secondary outcomes

  1. Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria in the Double-blind Maintenance Phase

    Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual though content) to a score of \>4 and an absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Current suicidal behavior as assessed by the C-SSRS (ie, an answer of "yes" to any of the questions on the suicidal behavior section of the C-SSRS 5) Violent or aggressive behavior resulting in clinically significant self-injury to another person, or property damage.

    Time frame: Baseline and Week 52/Early Termination

Other outcomes

  1. Percentage of Participants Meeting Stability Criteria in Double Blind Maintenance Phase

    Participants were assessed for stability using the following criteria:1) Outpatient status AND 2) Positive and Negative Syndrome Scale (PANSS) Total Score ≤ 70 AND 3) A score of ≤ 4 (moderate) on each of the following PANSS items (possible scores of 1 to 7 for each item): conceptual disorganization, suspiciousness hallucinatory behavior, unusual thought content, AND 4) Clinical Global Impression - Severity of Illness scale(CGI-S) score ≤ 4 (moderately ill) AND 5) No current suicidal behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS), defined as the following: An answer of "no" to each question on the Suicidal Behavior section of the C-SSRS AND an answer of "no" to Questions 4 and 5 on the Suicidal Ideation section of the C-SSRS, if completed, AND 6) No evidence of aggressive or violent behavior resulting in clinically significant self-injury, injury to another person, property damage.

    Time frame: Weeks 6, 12, 24, 36 and 52

  2. Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score - MMRM Analysis

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  3. Mean Change From Baseline in PANSS Total Score - Last-observation-carried-forward (LOCF) Analysis

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  4. Mean Change From Baseline in PANSS Positive Subscale Score - MMRM Analysis

    PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  5. Mean Change From Baseline in PANSS Positive Subscale Score - LOCF Analysis

    PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  6. Mean Change From Baseline in PANSS Negative Subscale Score - MMRM Analysis

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  7. Mean Change From Baseline in PANSS Negative Subscale Score - LOCF Analysis

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  8. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint - MMRM Analysis

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Weeks 6, 12, 24, 36 and 52

  9. Change From Baseline in CGI-S Score at Endpoint - LOCF Analysis

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  10. Clinical Global Impression - Improvement Score (CGI-I) at Endpoint - LOCF Analysis

    The rater or investigator would rate the participant's total improvement whether or not it is due entirely to study treatment. During Phase B, responses were compared to the participant's condition at Baseline of Phase B (for participants who entered Phase B directly after screening) or to the End of Phase A visit (for participants who participated in Phase A). During Phase C, responses were compared to the participant's condition at the End of Phase B visit. Response choices include: 0 = Not assessed, 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse.

    Time frame: Weeks 6, 12, 24, 36 and 52

  11. Mean Change From Baseline in Personal and Social Performance (PSP) Scale Score - MMRM Analysis

    The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.

    Time frame: Baseline and Weeks 24 and 52

  12. Mean Change From Baseline in PSP Scale Score - LOCF Analysis

    The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.

    Time frame: Baseline and Weeks 24 and 52

  13. Mean Change From Baseline in Global Assessment of Functioning (GAF) Scale Score - MMRM Analysis

    The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.

    Time frame: Baseline and Weeks 12, 24, 36 and 52

  14. Mean Change From Baseline in GAF Scale Score - LOCF Analysis

    The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.

    Time frame: Baseline and Weeks 12, 24, 36 and 52

  15. Percentage of Participants Who Discontinued Due to All Causes

    Analysis of the percentage of participants who discontinued due to all causes was based on all participants who have been randomized and taken one dose of IMP in the Double-blind Maintenance phase. The trial was completed by sponsor when efficacy was demonstrated at the first pre-specified interim analysis (45 impending relapse events) performed by an independent (unblinded) statistician.

    Time frame: Baseline to Week 52

  16. Mean Change From Baseline in PANSS Excited Component (PEC) Score - MMRM Analysis

    The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  17. Mean Change From Baseline in PEC Score - LOCF Analysis

    The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  18. Mean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - MMRM Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  19. Mean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - LOCF Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  20. Mean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - MMRM Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  21. Mean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - LOCF Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  22. Mean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - MMRM Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  23. Mean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - LOCF Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  24. Mean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - MMRM Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  25. Mean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - LOCF Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  26. Mean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - MMRM Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

  27. Mean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - LOCF Analysis

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: Baseline and Weeks 6, 12, 24, 36 and 52

07

Results

Posted Jan 13, 2017
Limitations and caveats
As the interim analysis results were positive, the trial was completed as it achieved the primary endpoint of a significant delay in time to impending relapse for participants randomized to brexpiprazole when compared to participants in placebo.

Participant flow

A total of 753 participants were screened at 49 trial sites in the following 7 countries: United States (US, including Puerto Rico), Malaysia, Colombia, Romania, Ukraine, Serbia, and Turkey.

Phase A (Conversion Phase)
Participant flow — Phase A (Conversion Phase)
MilestonePhase A (Conversion Phase)Phase B (Stabilization Phase)Phase C - Brexpiprazole (Double-Blind Maintenance Phase)Phase C - Placebo (Double-Blind Maintenance Phase)
Started406000
Completed346000
Not completed60000
Withdrew: Lost to follow-up3000
Withdrew: Met withdrawal criteria3000
Withdrew: Physician decision2000
Withdrew: Withdrawal by subject16000
Withdrew: Protocol violation2000
Withdrew: Lack of efficacy7000
Withdrew: Adverse event without impending relapse8000
Withdrew: Terminated study on interim analysis19000
Phase B (Stabilization Phase)
Participant flow — Phase B (Stabilization Phase)
MilestonePhase A (Conversion Phase)Phase B (Stabilization Phase)Phase C - Brexpiprazole (Double-Blind Maintenance Phase)Phase C - Placebo (Double-Blind Maintenance Phase)
Started046400
Completed020200
Not completed026200
Withdrew: Lost to follow-up01600
Withdrew: Met withdrawal criteria02200
Withdrew: Physician decision01100
Withdrew: Withdrawal by subject06000
Withdrew: Protocol violation0300
Withdrew: Lack of efficacy02100
Withdrew: Adverse event without impending relapse04300
Withdrew: Terminated study on interim analysis08600
Phase C (Double-Blind Maintenance Phase)
Participant flow — Phase C (Double-Blind Maintenance Phase)
MilestonePhase A (Conversion Phase)Phase B (Stabilization Phase)Phase C - Brexpiprazole (Double-Blind Maintenance Phase)Phase C - Placebo (Double-Blind Maintenance Phase)
Started0097105
Completed00149
Not completed008396
Withdrew: Lost to follow-up0046
Withdrew: Met withdrawal criteria0033
Withdrew: Physician decision0052
Withdrew: Withdrawal by subject0035
Withdrew: Protocol violation0020
Withdrew: Lack of efficacy00210
Withdrew: Lack of efficacy without ae001130
Withdrew: Adverse event without impending relapse0042
Withdrew: Terminated study on interim analysis004938

Outcome measures

PrimaryTime From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C.

The primary efficacy variable was time to impending relapse from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \>4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content).OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.The measure type, number is Hazard Ratio.

Time frame:
From randomization to time of exacerbation of psychotic symptoms/impending relapse - up to 52 weeks
Reported as:
Number · Days
Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C.
DaysBrexpiprazolePlacebo
Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C.0.292 (0.156 to 0.548)3.420 (1.825 to 6.411)
Statistical analysis
  • Brexpiprazole vs Placebo · Log Rank · p = <0.0001The log-rank test was based on time to exacerbation of psychotic symptoms/impending relapse.
SecondaryPercentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria in the Double-blind Maintenance Phase

Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual though content) to a score of \>4 and an absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Current suicidal behavior as assessed by the C-SSRS (ie, an answer of "yes" to any of the questions on the suicidal behavior section of the C-SSRS 5) Violent or aggressive behavior resulting in clinically significant self-injury to another person, or property damage.

Time frame:
Baseline and Week 52/Early Termination
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria in the Double-blind Maintenance Phase
percentage of participantsBrexpiprazolePlacebo
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria in the Double-blind Maintenance Phase13.5438.46
Statistical analysis
  • Brexpiprazole vs Placebo · Chi-squared · p = <0.0001
Other pre-specifiedPercentage of Participants Meeting Stability Criteria in Double Blind Maintenance Phase

Participants were assessed for stability using the following criteria:1) Outpatient status AND 2) Positive and Negative Syndrome Scale (PANSS) Total Score ≤ 70 AND 3) A score of ≤ 4 (moderate) on each of the following PANSS items (possible scores of 1 to 7 for each item): conceptual disorganization, suspiciousness hallucinatory behavior, unusual thought content, AND 4) Clinical Global Impression - Severity of Illness scale(CGI-S) score ≤ 4 (moderately ill) AND 5) No current suicidal behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS), defined as the following: An answer of "no" to each question on the Suicidal Behavior section of the C-SSRS AND an answer of "no" to Questions 4 and 5 on the Suicidal Ideation section of the C-SSRS, if completed, AND 6) No evidence of aggressive or violent behavior resulting in clinically significant self-injury, injury to another person, property damage.

Time frame:
Weeks 6, 12, 24, 36 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Stability Criteria in Double Blind Maintenance Phase
percentage of participantsBrexpiprazolePlacebo
Week 6 (N= 81, 84)92.5986.90
Week 12 (N= 73, 68)93.1586.76
Week 24 (N= 50, 36)96.0094.44
Week 36 (N= 33, 24)93.9483.33
Week 52 (N= 15, 9)86.6788.89
Last Visit (N= 96, 104)79.1756.73
Statistical analysis
  • Brexpiprazole vs Placebo · Chi-squared · p = 0.2296
  • Brexpiprazole vs Placebo · Chi-squared · p = 0.2051
  • Brexpiprazole vs Placebo · Chi-squared · p = 0.7354
  • Brexpiprazole vs Placebo · Chi-squared · p = 0.1977
  • Brexpiprazole vs Placebo · Chi-squared · p = 0.8734
  • Brexpiprazole vs Placebo · Chi-squared · p = 0.0007
Other pre-specifiedMean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score - MMRM Analysis

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)0.79 ± 1.314.09 ± 1.27
Week 12 (N= 73, 68)0.84 ± 1.736.15 ± 1.74
Week 24 (N= 50, 36)-1.88 ± 1.392.89 ± 1.55
Week 36 (N= 33, 24)-2.71 ± 1.483.33 ± 1.70
Week 52 (N= 15, 9)0.61 ± 3.346.92 ± 4.53
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0664 · Mean difference (final values): -3.30 · 95% CI -6.82 to 0.23
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0301 · Mean difference (final values): -5.31 · 95% CI -10.1 to -0.52
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0226 · Mean difference (final values): -4.77 · 95% CI -8.86 to -0.68
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0086 · Mean difference (final values): -6.03 · 95% CI -10.5 to -1.59
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2800 · Mean difference (final values): -6.31 · 95% CI -18.1 to 5.46
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0011 · Mean difference (final values): -4.42 · 95% CI -7.01 to -1.82
Other pre-specifiedMean Change From Baseline in PANSS Total Score - Last-observation-carried-forward (LOCF) Analysis

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Total Score - Last-observation-carried-forward (LOCF) Analysis
Units on a scaleBrexpiprazolePlacebo
Week 60.51 ± 1.403.56 ± 1.28
Week 121.55 ± 1.776.60 ± 1.62
Week 241.58 ± 1.889.17 ± 1.72
Week 362.49 ± 1.8910.51 ± 1.73
Week 523.25 ± 1.9411.20 ± 1.77
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0683 · Mean difference (final values): -3.04 · 95% CI -6.31 to 0.23
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0174 · Mean difference (final values): -5.05 · 95% CI -9.20 to -0.90
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0008 · Mean difference (final values): -7.59 · 95% CI -12.0 to -3.18
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0005 · Mean difference (final values): -8.02 · 95% CI -12.4 to -3.59
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0007 · Mean difference (final values): -7.95 · 95% CI -12.5 to -3.41
Other pre-specifiedMean Change From Baseline in PANSS Positive Subscale Score - MMRM Analysis

PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Positive Subscale Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)0.17 ± 0.421.28 ± 0.41
Week 12 (N= 73, 68)-0.06 ± 0.501.81 ± 0.51
Week 24 (N= 50, 36)-0.84 ± 0.460.72 ± 0.51
Week 36 (N= 33, 24)-0.97 ± 0.440.91 ± 0.51
Week 52 (N= 15, 9)-1.21 ± 0.731.50 ± 0.99
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0507 · Mean difference (final values): -1.11 · 95% CI -2.23 to 0.00
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0080 · Mean difference (final values): -1.87 · 95% CI -3.24 to -0.50
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0215 · Mean difference (final values): -1.56 · 95% CI -2.89 to -0.24
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0053 · Mean difference (final values): -1.88 · 95% CI -3.19 to -0.58
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.339 · Mean difference (final values): -2.71 · 95% CI -5.20 to -0.22
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = < 0.0001 · Mean difference (final values): -1.6 · 95% CI -2.32 to -0.88
Other pre-specifiedMean Change From Baseline in PANSS Positive Subscale Score - LOCF Analysis

PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Positive Subscale Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 60.30 ± 0.491.25 ± 0.45
Week 120.38 ± 0.592.24 ± 0.54
Week 240.49 ± 0.643.23 ± 0.59
Week 360.97 ± 0.633.91 ± 0.58
Week 520.99 ± 0.644.17 ± 0.59
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1093 · Mean difference (final values): -0.94 · 95% CI -2.10 to 0.21
  • Brexpiprazole vs Placebo · ANOVA · p = 0.0089 · Mean difference (final values): -1.86 · 95% CI -3.25 to -0.47
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0005 · Mean difference (final values): -2.74 · 95% CI -4.26 to -1.22
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -2.94 · 95% CI -4.43 to -1.44
  • Brexpiprazole vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -3.18 · 95% CI -4.70 to -1.66
Other pre-specifiedMean Change From Baseline in PANSS Negative Subscale Score - MMRM Analysis

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Negative Subscale Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)-0.04 ± 0.370.65 ± 0.35
Week 12 (N= 73, 68)-0.22 ± 0.430.55 ± 0.44
Week 24 (N= 50, 36)-0.78 ± 0.390.18 ± 0.42
Week 36 (N= 33, 24)-1.03 ± 0.470.02 ± 0.53
Week 52 (N= 15, 9)1.30 ± 1.370.87 ± 1.71
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1650 · Mean difference (final values): -0.69 · 95% CI -1.66 to 0.29
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2001 · Mean difference (final values): -0.78 · 95% CI -1.97 to 0.42
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0939 · Mean difference (final values): -0.95 · 95% CI -2.07 to 0.16
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1396 · Mean difference (final values): -1.05 · 95% CI -2.44 to 0.35
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.8470 · Mean difference (final values): 0.43 · 95% CI -4.14 to 5.00
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2258 · Mean difference (final values): -0.47 · 95% CI -1.24 to 0.3
Other pre-specifiedMean Change From Baseline in PANSS Negative Subscale Score - LOCF Analysis

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Negative Subscale Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6-0.12 ± 0.390.63 ± 0.35
Week 12-0.17 ± 0.461.06 ± 0.42
Week 24-0.08 ± 0.491.47 ± 0.44
Week 36-0.14 ± 0.511.44 ± 0.46
Week 520.39 ± 0.541.63 ± 0.49
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0981 · Mean difference (final values): -0.76 · 95% CI -1.65 to 0.14
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0264 · Mean difference (final values): -1.22 · 95% CI -2.30 to -0.15
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0078 · Mean difference (final values): -1.55 · 95% CI -2.69 to -0.42
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0101 · Mean difference (final values): -1.57 · 95% CI -2.77 to -0.38
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0516 · Mean difference (final values): -1.24 · 95% CI -2.50 to 0.01
Other pre-specifiedChange From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint - MMRM Analysis

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)-0.01 ± 0.090.26 ± 0.09
Week 12 (N= 73, 68)-0.01 ± 0.110.37 ± 0.11
Week 24 (N= 50, 36)-0.16 ± 0.100.21 ± 0.10
Week 36 (N= 33, 24)-0.31 ± 0.110.25 ± 0.12
Week 52 (N= 15, 9)-0.23 ± 0.170.28 ± 0.22
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0279 · Mean difference (final values): -0.28 · 95% CI -0.53 to -0.03
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0117 · Mean difference (final values): -0.39 · 95% CI -0.68 to -0.09
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0105 · Mean difference (final values): -0.37 · 95% CI -0.64 to -0.09
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0007 · Mean difference (final values): -0.56 · 95% CI -0.87 to -0.25
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0780 · Mean difference (final values): -0.51 · 95% CI -1.09 to 0.06
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0006 · Mean difference (final values): -0.35 · 95% CI -0.54 to -0.15
Other pre-specifiedChange From Baseline in CGI-S Score at Endpoint - LOCF Analysis

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in CGI-S Score at Endpoint - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6-0.08 ± 0.090.17 ± 0.09
Week 12-0.04 ± 0.110.32 ± 0.10
Week 24-0.03 ± 0.110.47 ± 0.10
Week 36-0.00 ± 0.110.56 ± 0.10
Week 520.02 ± 0.110.55 ± 0.11
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0284 · Mean difference (final values): -0.25 · 95% CI -0.47 to -0.03
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0056 · Mean difference (final values): -0.36 · 95% CI -0.62 to -0.11
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): -0.50 · 95% CI -0.76 to -0.24
  • Brexpiprazole vs Placebo · ANCOVA · p = <.0001 · Mean difference (final values): -0.56 · 95% CI -0.82 to -0.30
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): -0.53 · 95% CI -0.79 to -0.26
Other pre-specifiedClinical Global Impression - Improvement Score (CGI-I) at Endpoint - LOCF Analysis

The rater or investigator would rate the participant's total improvement whether or not it is due entirely to study treatment. During Phase B, responses were compared to the participant's condition at Baseline of Phase B (for participants who entered Phase B directly after screening) or to the End of Phase A visit (for participants who participated in Phase A). During Phase C, responses were compared to the participant's condition at the End of Phase B visit. Response choices include: 0 = Not assessed, 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse.

Time frame:
Weeks 6, 12, 24, 36 and 52
Reported as:
Mean · Units on a scale
Clinical Global Impression - Improvement Score (CGI-I) at Endpoint - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 63.68 ± 0.984.00 ± 1.14
Week 123.66 ± 1.194.10 ± 1.30
Week 243.67 ± 1.274.30 ± 1.32
Week 363.71 ± 1.274.39 ± 1.30
Week 523.77 ± 1.264.40 ± 1.32
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0387 · Mean difference (final values): -0.31 · 95% CI -0.60 to -0.20
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0185 · Mean difference (final values): -0.41 · 95% CI -0.75 to -0.07
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0010 · Mean difference (final values): -0.61 · 95% CI -0.97 to -0.24
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0004 · Mean difference (final values): -0.66 · 95% CI -1.02 to -0.30
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0009 · Treatment difference: -0.61 · 95% CI -0.96 to -0.25
Other pre-specifiedMean Change From Baseline in Personal and Social Performance (PSP) Scale Score - MMRM Analysis

The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.

Time frame:
Baseline and Weeks 24 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Personal and Social Performance (PSP) Scale Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 24 (N= 50, 36)18.85 ± 1.5117.84 ± 1.82
Week 52 (N= 15, 9)18.63 ± 2.7612.55 ± 3.48
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.6525 · Mean difference (final values): 1.01 · 95% CI -3.47 to 5.49
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1677 · Mean difference (final values): 6.08 · 95% CI -2.71 to 14.87
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2347 · Mean difference (final values): 3.55 · 95% CI -2.41 to 9.5
Other pre-specifiedMean Change From Baseline in PSP Scale Score - LOCF Analysis

The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.

Time frame:
Baseline and Weeks 24 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PSP Scale Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 2415.20 ± 1.4111.41 ± 1.32
Week 5215.06 ± 1.4310.31 ± 1.34
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0285 · Mean difference (final values): 3.79 · 95% CI 0.40 to 7.17
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0071 · Mean difference (final values): 4.75 · 95% CI 1.31 to 8.18
Other pre-specifiedMean Change From Baseline in Global Assessment of Functioning (GAF) Scale Score - MMRM Analysis

The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.

Time frame:
Baseline and Weeks 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Global Assessment of Functioning (GAF) Scale Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 12 (N= 73, 68)1.59 ± 1.27-0.03 ± 1.29
Week 24 (N= 50, 36)3.74 ± 1.421.09 ± 1.57
Week 36 (N= 33, 24)4.71 ± 1.500.21 ± 1.67
Week 52 (N= 15, 9)5.72 ± 1.87-0.16 ± 2.37
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.3290 · Mean difference (final values): 1.61 · 95% CI -1.65 to 4.88
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1765 · Mean difference (final values): 2.66 · 95% CI -1.22 to 6.54
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0331 · Mean difference (final values): 4.50 · 95% CI 0.38 to 8.63
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0522 · Mean difference (final values): 5.88 · 95% CI -0.06 to 11.82
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0281 · Mean difference (final values): 3.66 · 95% CI 0.41 to 6.92
Other pre-specifiedMean Change From Baseline in GAF Scale Score - LOCF Analysis

The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.

Time frame:
Baseline and Weeks 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in GAF Scale Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 120.44 ± 1.26-3.44 ± 1.17
Week 240.85 ± 1.37-4.51 ± 1.27
Week 360.97 ± 1.35-5.84 ± 1.25
Week 520.55 ± 1.38-6.01 ± 1.28
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0111 · Mean difference (final values): 3.88 · 95% CI 0.90 to 6.86
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0014 · Mean difference (final values): 5.36 · 95% CI 2.10 to 8.62
  • Brexpiprazole vs Placebo · ANCOVA · p = <.0001 · Mean difference (final values): 6.81 · 95% CI 3.61 to 10.00
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): 6.55 · 95% CI 3.28 to 9.83
Other pre-specifiedPercentage of Participants Who Discontinued Due to All Causes

Analysis of the percentage of participants who discontinued due to all causes was based on all participants who have been randomized and taken one dose of IMP in the Double-blind Maintenance phase. The trial was completed by sponsor when efficacy was demonstrated at the first pre-specified interim analysis (45 impending relapse events) performed by an independent (unblinded) statistician.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of particpants
Percentage of Participants Who Discontinued Due to All Causes
Percentage of particpantsBrexpiprazolePlacebo
Percentage of Participants Who Discontinued Due to All Causes34.3854.81
Statistical analysis
  • Brexpiprazole vs Placebo · Log Rank · p = 0.0014
Other pre-specifiedMean Change From Baseline in PANSS Excited Component (PEC) Score - MMRM Analysis

The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Excited Component (PEC) Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)0.32 ± 0.230.74 ± 0.22
Week 12 (N= 73, 68)0.50 ± 0.341.16 ± 0.35
Week 24 (N= 50, 36)-0.06 ± 0.310.45 ± 0.36
Week 36 (N= 33, 24)0.10 ± 0.331.25 ± 0.40
Week 52 (N= 15, 9)-0.04 ± 0.461.00 ± 0.59
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1577 · Mean difference (final values): -0.43 · 95% CI -1.02 to 0.17
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1685 · Mean difference (final values): -0.66 · 95% CI -1.61 to 0.28
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2815 · Mean difference (final values): -0.50 · 95% CI -1.43 to 0.42
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0286 · Mean difference (final values): -1.14 · 95% CI -2.16 to -0.12
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1803 · Mean difference (final values): -1.03 · 95% CI -2.58 to 0.51
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0077 · Mean difference (final values): -0.65 · 95% CI -1.12 to -0.17
Other pre-specifiedMean Change From Baseline in PEC Score - LOCF Analysis

The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PEC Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 60.38 ± 0.270.81 ± 0.25
Week 120.73 ± 0.361.36 ± 0.33
Week 240.78 ± 0.421.86 ± 0.38
Week 360.89 ± 0.412.23 ± 0.38
Week 520.82 ± 0.412.35 ± 0.38
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1852 · Mean difference (final values): -0.42 · 95% CI -1.06 to 0.21
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1430 · Mean difference (final values): -0.63 · 95% CI -1.47 to 0.21
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0323 · Mean difference (final values): -1.08 · 95% CI -2.06 to -0.09
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0071 · Mean difference (final values): -1.34 · 95% CI -2.31 to -0.37
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0023 · Mean difference (final values): -1.54 · 95% CI -2.52 to -0.56
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - MMRM Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)-0.10 ± 0.451.24 ± 0.44
Week 12 (N= 73, 68)-0.18 ± 0.581.83 ± 0.58
Week 24 (N= 50, 36)-0.82 ± 0.540.77 ± 0.60
Week 36 (N= 33, 24)-1.35 ± 0.570.93 ± 0.63
Week 52 (N= 15, 9)-1.62 ± 0.831.78 ± 1.05
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0288 · Mean difference (final values): -1.34 · 95% CI -2.54 to -0.14
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0128 · Mean difference (final values): -2.02 · 95% CI -3.60 to -0.44
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0462 · Mean difference (final values): -1.59 · 95% CI -3.15 to 0.03
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0074 · Mean difference (final values): -2.29 · 95% CI -3.94 to -0.64
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0136 · Mean difference (final values): -3.40 · 95% CI -6.05 to -0.75
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -1.91 · 95% CI -2.84 to -0.97
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - LOCF Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 60.05 ± 0.501.13 ± 0.46
Week 120.10 ± 0.612.03 ± 0.56
Week 240.25 ± 0.663.08 ± 0.61
Week 360.60 ± 0.663.69 ± 0.60
Week 520.58 ± 0.664.02 ± 0.60
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0695 · Mean difference (final values): -1.08 · 95% CI -2.26 to 0.09
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0089 · Mean difference (final values): -1.93 · 95% CI -3.38 to -0.49
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0004 · Mean difference (final values): -2.83 · 95% CI -4.39 to -1.27
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -3.09 · 95% CI -4.63 to -1.54
  • Brexpiprazole vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -3.44 · 95% CI -4.99 to -1.89
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - MMRM Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)0.02 ± 0.380.68 ± 0.36
Week 12 (N= 73, 68)-0.01 ± 0.450.80 ± 0.45
Week 24 (N= 50, 36)-0.71 ± 0.400.46 ± 0.43
Week 36 (N= 33, 24)-0.80 ± 0.500.70 ± 0.56
Week 52 (N= 15, 9)1.37 ± 1.391.06 ± 1.77
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1969 · Mean difference (final values): -0.66 · 95% CI -1.66 to 0.35
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2007 · Mean difference (final values): -0.80 · 95% CI -2.04 to 0.43
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0436 · Mean difference (final values): -1.17 · 95% CI -2.30 to -0.03
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0444 · Mean difference (final values): -1.51 · 95% CI -2.97 to -0.04
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.8927 · Mean difference (final values): 0.31 · 95% CI -4.40 to 5.02
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2154 · Mean difference (final values): -0.52 · 95% CI -1.34 to 0.31
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - LOCF Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6-0.24 ± 0.400.61 ± 0.36
Week 12-0.15 ± 0.481.09 ± 0.43
Week 24-0.09 ± 0.491.50 ± 0.44
Week 36-0.07 ± 0.521.56 ± 0.47
Week 520.34 ± 0.561.57 ± 0.50
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0707 · Mean difference (final values): -0.85 · 95% CI -1.78 to 0.07
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0276 · Mean difference (final values): -1.24 · 95% CI -2.35 to -0.14
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0065 · Mean difference (final values): -1.59 · 95% CI -2.72 to -0.45
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0085 · Mean difference (final values): -1.63 · 95% CI -2.84 to -0.42
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0630 · Mean difference (final values): -1.23 · 95% CI -2.52 to 0.07
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - MMRM Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)-0.18 ± 0.310.32 ± 0.30
Week 12 (N= 73, 68)-0.44 ± 0.380.69 ± 0.39
Week 24 (N= 50, 36)-1.26 ± 0.340.27 ± 0.38
Week 36 (N= 33, 24)-1.31 ± 0.440.17 ± 0.50
Week 52 (N= 15, 9)-0.37 ± 0.99-0.30 ± 1.24
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2251 · Mean difference (final values): -0.51 · 95% CI -1.33 to 0.31
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0368 · Mean difference (final values): -1.13 · 95% CI -2.19 to -0.07
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0024 · Mean difference (final values): -1.53 · 95% CI -2.51 to -0.56
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0293 · Mean difference (final values): -1.48 · 95% CI -2.80 to -0.15
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.9632 · Mean difference (final values): -0.07 · 95% CI -3.32 to 3.17
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0029 · Mean difference (final values): -0.99 · 95% CI -1.63 to -0.34
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - LOCF Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6-0.32 ± 0.340.33 ± 0.31
Week 12-0.19 ± 0.411.19 ± 0.38
Week 24-0.29 ± 0.441.76 ± 0.41
Week 360.00 ± 0.451.95 ± 0.42
Week 520.29 ± 0.481.97 ± 0.45
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1062 · Mean difference (final values): -0.65 · 95% CI -1.44 to 0.14
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0051 · Mean difference (final values): -1.37 · 95% CI -2.33 to -0.42
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -2.05 · 95% CI -3.08 to -1.01
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0004 · Mean difference (final values): -1.94 · 95% CI -3.00 to -0.89
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0035 · Mean difference (final values): -1.69 · 95% CI -2.81 to -0.56
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - MMRM Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)0.19 ± 0.190.55 ± 0.18
Week 12 (N= 73, 68)0.33 ± 0.280.82 ± 0.29
Week 24 (N= 50, 36)-0.26 ± 0.270.81 ± 0.31
Week 36 (N= 33, 24)-0.13 ± 0.290.94 ± 0.34
Week 52 (N= 15, 9)-0.20 ± 0.400.94 ± 0.50
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1465 · Mean difference (final values): -0.36 · 95% CI -0.85 to 0.13
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2154 · Mean difference (final values): -0.49 · 95% CI -1.27 to 0.29
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.2696 · Mean difference (final values): -0.44 · 95% CI -1.23 to 0.35
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0179 · Mean difference (final values): -1.07 · 95% CI -1.95 to -0.19
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0875 · Mean difference (final values): -1.14 · 95% CI -2.46 to 0.18
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.0021 · Mean difference (final values): -0.66 · 95% CI -1.08 to -0.24
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - LOCF Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 60.32 ± 0.220.65 ± 0.21
Week 120.52 ± 0.300.94 ± 0.28
Week 240.50 ± 0.361.31 ± 0.33
Week 360.57 ± 0.361.63 ± 0.33
Week 520.49 ± 0.371.75 ± 0.34
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.2135 · Mean difference (final values): -0.33 · 95% CI -0.86 to 0.19
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.2437 · Mean difference (final values): -0.42 · 95% CI -1.13 to 0.29
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0635 · Mean difference (final values): -0.81 · 95% CI -1.66 to 0.05
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0144 · Mean difference (final values): -1.07 · 95% CI -1.92 to -0.22
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0046 · Mean difference (final values): -1.26 · 95% CI -2.12 to -0.39
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - MMRM Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - MMRM Analysis
Units on a scaleBrexpiprazolePlacebo
Week 6 (N= 81, 84)0.19 ± 0.250.66 ± 0.24
Week 12 (N= 73, 68)0.54 ± 0.290.78 ± 0.29
Week 24 (N= 50, 36)0.61 ± 0.280.58 ± 0.32
Week 36 (N= 33, 24)0.46 ± 0.330.71 ± 0.39
Week 52 (N= 15, 9)0.04 ± 0.430.28 ± 0.56
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.1640 · Mean difference (final values): -0.47 · 95% CI -1.14 to 0.19
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.5466 · Mean difference (final values): -0.24 · 95% CI -1.04 to 0.55
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.9417 · Mean difference (final values): 0.03 · 95% CI -0.81 to 0.87
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.6257 · Mean difference (final values): -0.25 · 95% CI -1.25 to 0.76
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.7437 · Mean difference (final values): -0.23 · 95% CI -1.68 to 1.21
  • Brexpiprazole vs Placebo · Mixed Models Analysis · p = 0.4506 · Mean difference (final values): -0.17 · 95% CI -0.62 to 0.28
Other pre-specifiedMean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - LOCF Analysis

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
Baseline and Weeks 6, 12, 24, 36 and 52
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - LOCF Analysis
Units on a scaleBrexpiprazolePlacebo
Week 60.19 ± 0.270.85 ± 0.25
Week 120.86 ± 0.321.41 ± 0.30
Week 241.07 ± 0.321.64 ± 0.30
Week 361.09 ± 0.321.79 ± 0.30
Week 521.17 ± 0.311.88 ± 0.29
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0467 · Mean difference (final values): -0.67 · 95% CI -1.32 to -0.06
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1599 · Mean difference (final values): -0.55 · 95% CI -1.33 to 0.22
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1417 · Mean difference (final values): -0.58 · 95% CI -1.35 to 0.19
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0724 · Mean difference (final values): -0.70 · 95% CI -1.47 to 0.06
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0608 · Mean difference (final values): -0.72 · 95% CI -1.47 to 0.03

Adverse events

Collected over Adverse events reported from the signing of the informed consent throughout the stabilization and treatment period followed by a follow-up phone call or clinic visit (study physician's discretion) of 30 (+2) days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Blind Stabilization Phase—34/464 (7.3%)148/464 (31.9%)
Brexpiprazole (Double-blind Maintenance Phase)—3/97 (3.1%)0/97 (0%)
Placebo (Double-blnd Maintenance Phase)—11/104 (10.6%)0/104 (0%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSingle Blind Stabilization PhaseBrexpiprazole (Double-blind Maintenance Phase)Placebo (Double-blnd Maintenance Phase)
SchizophreniaPsychiatric disorders22/4641/975/104
Psychotic disorderPsychiatric disorders0/4641/974/104
Hepatic enzyme increasedInvestigations0/4641/970/104
Angina unstableCardiac disorders0/4640/971/104
ArrhythmiaCardiac disorders0/4640/971/104
Suicidal ideationPsychiatric disorders3/4640/971/104
HypertensionVascular disorders0/4640/971/104
Psychotic disorderPsychiatric disorders3/4640/970/104
Gun shot woundInjury, poisoning and procedural complications1/4640/970/104
Oedema peripheralGeneral disorders1/4640/970/104
Most frequent other events
Most frequent other events
EventSingle Blind Stabilization PhaseBrexpiprazole (Double-blind Maintenance Phase)Placebo (Double-blnd Maintenance Phase)
InsomniaNervous system disorders56/4640/970/104
AkathisiaNervous system disorders42/4640/970/104
AgitationPsychiatric disorders30/4640/970/104
SchizophreniaNervous system disorders28/4640/970/104
Weight increasedInvestigations24/4640/970/104
HeadacheNervous system disorders23/4640/970/104

Baseline characteristics

The enrolled sample was defined as all participants who signed the informed consent for the trial and entered Phase A or Phase B.

Age, Continuous
Age, Continuous(years)Phase C - Brexpiprazole (Double-Blind Maintenance Phase)Phase C - Placebo (Double-Blind Maintenance Phase)Total
Mean38.8 ± 10.741.6 ± 10.640.2 ± 10.7
Gender
Gender(Participants)Phase C - Brexpiprazole (Double-Blind Maintenance Phase)Phase C - Placebo (Double-Blind Maintenance Phase)Total
Female394079
Male5865123
08

Study locations

49 sites
  • Anaheim, California 92805, United States
  • Cerritos, California 90703, United States
  • Garden Grove, California 92845, United States
  • San Diego, California 92102, United States
  • San Diego, California 92103, United States
  • Tampa, Florida 33613, United States
  • Hoffman Estates, Illinois 60169, United States
  • St. Charles, Missouri 63304, United States
  • St. Louis, Missouri 63141, United States
  • North Platte, Nebraska 69101, United States
  • Las Vegas, Nevada 89102, United States
  • Memphis, Tennessee 38119, United States
  • Dallas, Texas 75231, United States
  • Richmond, Virginia 23230, United States
  • Barranquilla, 00000, Colombia
  • Bello, 00000, Colombia
  • Bogota, 00000, Colombia
  • Pereira, 00000, Colombia
  • Kota Bahru, Kelantan 15586, Malaysia
  • Kajang, Selangor 43000, Malaysia
  • Kuala Lumpur, 56000, Malaysia
  • Kuala Lumpur, 59100, Malaysia
  • Sabah, 88815, Malaysia
  • San Juan, 00918, Puerto Rico
  • San Juan, 00927, Puerto Rico
  • Arad, 310022, Romania
  • Brasov, 500123, Romania
  • Bucuresti, 041914, Romania
  • Craiova, 200473, Romania
  • Focsani, 620165, Romania
  • Iasi, 700282, Romania
  • Pitesti, 110069, Romania
  • Targoviste, 130086, Romania
  • Belgrade, 11000, Serbia
  • Belgrade, 11040, Serbia
  • Kragujevac, 34000, Serbia
  • Novi Knezevac, 23330, Serbia
  • Novi Sad, 21000, Serbia
  • Denizli, 20070, Turkey
  • Diyarbakir, 21280, Turkey
  • Kocaeli, 41380, Turkey
  • Kharkiv, 61036, Ukraine
  • Kharkiv, 61068, Ukraine
  • Kherson,Vil. Stepanivka, 73488, Ukraine
  • Kyiv, 02660, Ukraine
  • Kyiv, 04080, Ukraine
  • Lviv, 79021, Ukraine
  • Odesa, 65014, Ukraine
  • Simferopol, 95006, Ukraine
09

References and documents

Publications

  • Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793. PubMed 35235720 ↗
  • Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan. PubMed 34901863 ↗
  • Correll CU, Shi L, Weiss C, Hobart M, Eramo A, Duffy RA, Weiller E, Baker RA. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2019 Oct;24(5):507-517. doi: 10.1017/S1092852918001086. PubMed 30306884 ↗
  • Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, Carson WH, Sanchez R, Nyilas M, Weiller E. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. Int J Neuropsychopharmacol. 2017 Jan 1;20(1):11-21. doi: 10.1093/ijnp/pyw076. PubMed 27566723 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2012
First posted
Aug 20, 2012
Start
Oct 2012
Primary completionActual
Jan 2015
CompletionActual
Feb 2015
Results first posted
Jan 13, 2017
Last update
Jan 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01668797
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2012
Start date
Oct 2012
Primary completion
Jan 2015
Completion
Feb 2015
Results posted
Jan 13, 2017
Last update
Jan 13, 2017

Study contacts

Aleksandar Skuban, M.D.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion